These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34692255)

  • 1. Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    You C; Li X; Du Y; Wang H; Zhang X; Wei T; Wang A
    PeerJ; 2021; 9():e12248. PubMed ID: 34692255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis.
    Ji J; Yao Y; Guan F; Sun L; Zhang G
    J Cancer Res Ther; 2022 Dec; 18(7):1884-1893. PubMed ID: 36647946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non-muscle-invasive bladder cancer.
    Luo S; Wu Y; Yang R; Liu J; Wusimanjiang W; Zhan W; Si E; Chen L; Lin H; Chen J; Huang B
    Urol Oncol; 2024 Dec; 42(12):450.e1-450.e12. PubMed ID: 39366792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis.
    Cheng C; Qiu D; Chen J; Zu X; Liu J; Li H; Hu J; Yi Z; He T; Chen Z; Cui Y
    Front Pharmacol; 2021; 12():707271. PubMed ID: 34603020
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
    Huang B; Zheng J; Yao Z; Fan W; Qiu S; Chen L; Chen J
    World J Urol; 2019 May; 37(5):823-829. PubMed ID: 30191393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy
    Zhou Z; Cui Y; Huang S; Chen Z; Zhang Y
    Front Oncol; 2021; 11():651657. PubMed ID: 34123803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intra-arterial chemotherapy combined with intravesical chemotherapy for high-risk non-muscle invasive bladder cancer: A protocol for a systematic review and meta-analysis.
    Li X; Ma H; Shu K; Wang L; Ding D
    Medicine (Baltimore); 2019 Dec; 98(51):e18516. PubMed ID: 31861039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis.
    Huang D; Jin YH; Weng H; Huang Q; Zeng XT; Wang XH
    Front Oncol; 2019; 9():121. PubMed ID: 30881921
    [No Abstract]   [Full Text] [Related]  

  • 10. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive bladder cancer: results of a retrospective study.
    Chen J; Zhang Z; Nie Z; Qiu J
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13905-13913. PubMed ID: 37540255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.
    Chen Q; Zhang B; Dong Y; Mo X; Zhang L; Huang W; Jiang H; Xia J; Zhang S
    BMC Cancer; 2018 Apr; 18(1):486. PubMed ID: 29703164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma.
    Chen Q; Zhang B; Dong Y; Mo X; Zhang L; Xia J; Zhang J; Zhang S
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):723-730. PubMed ID: 32123960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
    Perlis N; Zlotta AR; Beyene J; Finelli A; Fleshner NE; Kulkarni GS
    Eur Urol; 2013 Sep; 64(3):421-30. PubMed ID: 23830475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
    Sun F; Zhao R; Zhu Y; Cui D; Wang X; Han B; Liang S; Liu H; Sun X; Zhao F; Xu D; Xia S
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1099-1107. PubMed ID: 28421294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
    Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
    Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
    Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
    Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.